slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 96,741
Current window 75,661-75,690
Pages 3,225
Rows per page 30
Component
75,661-75,690 of 96,741
379
The slide uses a direct quote from a pediatric endocrinologist to undermine the drug's clinical value.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
380
The slide uses direct quotes to expose the contradiction between the physician's knowledge of drug inefficacy and their continued prescription behavior.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
381
The slide uses direct quotes from an expert consultation to contrast grassroots patient enthusiasm with professional indifference.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
382
The slide uses a Q&A transcript format to highlight the physician's frustration and lack of guidance from the manufacturer.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
383
The slide presents a quote from an anonymous pediatric endocrinologist criticizing Dr. Miller's influence and medical recommendations.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
384
The slide uses a pull-quote style to highlight the expert's hesitation and lack of full support.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
385
The slide highlights a potential safety concern raised by an expert, specifically regarding pre-diabetic and obese patients.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
387
The slide uses Q&A transcripts to undermine the credibility of the company's marketing claims.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
388
The slide uses a combination of summary text and direct interview transcripts to build a case against the drug's adoption.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
389
The slide uses a Q&A format to highlight expert skepticism regarding the drug's necessity and cost-effectiveness.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
390
The slide highlights a negative expert opinion on a drug being repurposed for PWS.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
391
The slide uses a 'quote-sandwich' technique: a summary paragraph followed by verbatim Q&A transcripts with highlighted key phrases.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
392
The slide uses direct quotes and Q&A excerpts to build a case against the safety of the drug Vykat in the context of PWS treatment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
393
The slide uses highlighted text to emphasize key concerns about Vykat's safety profile and Miller's private skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
395
The slide uses a Q&A format to highlight the physician's reluctance to prescribe Vykat and their familiarity with the risks of diazoxide.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
396
The slide uses direct quotes from a pediatric endocrinologist to undermine the company's commercial narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
397
The slide uses direct quotes to build a case against the company's commercial execution.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
398
The slide uses a Q&A format to expose the contradiction between the drug's intended use and its actual clinical viability.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
399
The slide uses direct quotes from an expert consultation to illustrate market resistance.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
400
The slide uses a combination of summary bullet points and verbatim Q&A transcripts to highlight the expert's negative assessment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
401
The slide uses a direct quote to undermine the perceived value of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
402
The slide highlights a potential competitive threat to Vykat from generic diazoxide.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
403
The slide highlights a contradiction between the drug's intended use and its physiological impact on a vulnerable patient population.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
406
The slide uses a Q&A format to highlight physician reluctance.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
407
The slide presents a summary of an expert interview, highlighting the endocrinologist's preference for GLP-1s over Vykat for PWS patients.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
408
The slide uses direct quotes from an endocrinologist to frame potential medical risks as a barrier to adoption.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
409
The slide uses direct quotes to build a narrative of expert doubt.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
410
The slide uses Q&A transcripts to highlight the expert's skepticism regarding Vykat's value proposition.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
411
The slide uses a Q&A format to highlight the administrative burden and slow approval process for the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
412
The slide uses a Q&A transcript format to validate the claim of trial unblinding.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit